MMQ0 Stock Chart & Stats
€18.85
-€0.45(-5.84%)
At close: 4:00 PM EST
€18.85
-€0.45(-5.84%)
Day’s Range― - ―
52-Week Range€5.46 - €23.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)513.00
Market Cap
€5.13B
Enterprise Value€2.40B
Total Cash (Recent Filing)€373.42M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 06, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding132,743,260
10 Day Avg. Volume263
30 Day Avg. Volume513
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)3.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€47.64Price Target Upside152.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.98
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late‑stage Clinical MomentumA clustered late‑stage program with staggered pivotal readouts and Breakthrough Therapy designation materially reduces single‑trial binary risk and creates multiple regulatory and commercial inflection points. Robust powering and Part B follow‑up improve chances of durable efficacy and label breadth, supporting long‑term market entry plans.
Solid Near‑term Liquidity RunwayA multi‑year cash runway provides durable financial flexibility to complete multiple Phase III programs and fund commercialization readiness without immediate dependency on dilutive bridge financings. This allows management to execute trials, regulatory interactions and launch planning while absorbing near‑term operational spending increases.
Material Equity Raise Strengthens Balance SheetA large primary equity offering materially increases long‑term funding capacity to support R&D, NDA prep and commercial build. While dilutive, the structural effect is enhanced liquidity and the ability to invest in launch infrastructure and manufacturing scale, reducing execution risk tied to funding gaps.
Bears Say
Pre‑revenue, Sustained Cash BurnOperating losses and persistent negative free cash flow create a structural reliance on equity capital to fund operations. Even with new proceeds, repeated rounds or large financings may be required for commercialization, raising dilution risk and pressuring long‑term capital efficiency until product revenue materializes.
Trial Design/placebo‑response RiskA high placebo signal from earlier trials is a structural clinical risk that can blunt observed treatment effects and complicate regulatory interpretation. Even with Phase III design adjustments, persistent placebo dynamics could reduce effect sizes, affect statistical success, and increase the probability of additional studies or label restrictions.
Regulatory, Payer And Coding UncertaintyUncertainty on NDA strategy, FDA discussions and post‑approval coding/reimbursement pathways are durable commercialization risks. Even with positive efficacy, unclear payer coverage and coding could limit access, constrain pricing and slow adoption, materially impacting long‑term revenue realization and clinic economics.
Definium Therapeutics News
MMQ0 FAQ
What was Definium Therapeutics, Inc.’s price range in the past 12 months?
Definium Therapeutics, Inc. lowest stock price was €5.46 and its highest was €23.00 in the past 12 months.
What is Definium Therapeutics, Inc.’s market cap?
Definium Therapeutics, Inc.’s market cap is €5.13B.
When is Definium Therapeutics, Inc.’s upcoming earnings report date?
Definium Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 33 days.
How were Definium Therapeutics, Inc.’s earnings last quarter?
Definium Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -€0.62 earnings per share for the quarter, missing the consensus estimate of -€0.43 by -€0.191.
Is Definium Therapeutics, Inc. overvalued?
According to Wall Street analysts Definium Therapeutics, Inc.’s price is currently Undervalued.
Does Definium Therapeutics, Inc. pay dividends?
Definium Therapeutics, Inc. does not currently pay dividends.
What is Definium Therapeutics, Inc.’s EPS estimate?
Definium Therapeutics, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Definium Therapeutics, Inc. have?
Definium Therapeutics, Inc. has 132,743,260 shares outstanding.
What happened to Definium Therapeutics, Inc.’s price movement after its last earnings report?
Definium Therapeutics, Inc. reported an EPS of -€0.62 in its last earnings report, missing expectations of -€0.43. Following the earnings report the stock price went down -3.342%.
Which hedge fund is a major shareholder of Definium Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DE:MMQ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Definium Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€47.64 (152.72% Upside)
€47.64 (152.72% Upside)
Blogger Sentiment
Bullish
DE:MMQ0 Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
524.15%
12-Months-Change
Fundamentals
Return on Equity
-102.48%
Trailing 12-Months
Asset Growth
45.75%
Trailing 12-Months
Company Description
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
MMQ0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical momentum (multiple Phase III programs with imminent topline readouts, Breakthrough Therapy designation in GAD, high statistical power in key studies), a clear commercialization plan and a solid cash position ($373.4M runway into 2028). These positives are tempered by materially higher operating expenses and a sizable YOY increase in net loss (driven by program investment and a non-cash warrant valuation change), design-related placebo risk from Phase II, and remaining regulatory and payer uncertainties that could affect timing and labeling. On balance, management’s message is forward-looking and execution-focused with meaningful near-term inflection points.View all DE:MMQ0 earnings summariesMMQ0 Stock 12 Month Forecast
Average Price Target
€47.64
▲(152.72% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―
Options Prices
Currently, No data available
---